VANCOUVER, British Columbia, Sept. 21, 2026 (GLOBE NEWSWIRE) — Eldorado Gold Corporation (“Eldorado” or the “Company”) (TSX: ELD, NYSE: EGO) will release its Third Quarter 2026 Financial and Operational Results after the market closes on Wednesday, October 28, 2026, and will host a conference call on Thursday, October 29, 2026 at 9:00 AM ET (6:00 AM PT). This reporting date differs slightly from the schedule published on January 20, 2026.
Q3 2026 Financial and Operational Results Call Details
Participants may elect to pre-register for the conference call via this link:https://dpregister.com/sreg/10211449/104b751968a. Upon registration, participants will receive a calendar invitation by email with dial in details and a unique PIN. This will allow participants to bypass the operator queue and connect directly to the conference. Registration will remain open until the end of the conference call.
About Eldorado Gold
Eldorado is a gold and base metals producer with mining, development and exploration operations in Canada, Türkiye, and Greece. The Company has a highly skilled and dedicated workforce, safe and responsible operations, a portfolio of high-quality assets, and long-term partnerships with local communities. Eldorado’s common shares trade on the Toronto Stock Exchange (TSX: ELD) and the New York Stock Exchange (NYSE: EGO).
Take Advantage of Limited-Time Deals on Move-in Ready Homes
THE WOODLANDS, Texas, Sept. 21, 2026 (GLOBE NEWSWIRE) — LGI Homes, Inc. (NASDAQ: LGIH), one of the nation’s leading homebuilders, announced that its Make Your Move National Sales Event is now underway, giving homebuyers across the country access to limited-time savings and incentives on select move-in ready homes on LGI Homes and Terrata Homes.
The national sales event began September 18 and features opportunities designed to make purchasing a new home more attainable. At LGI Homes communities, buyers can take advantage of incentives on select inventory, including builder-paid closing costs, included upgrades and special interest rate incentives. With a variety of move-in ready homes available, buyers have the opportunity to find a new home and move-in before the holiday season while taking advantage of these limited-time offers.
Through LGI Homes’ luxury brand, Terrata Homes, buyers can also take advantage of $25,000 in Flex Cash on select homes during the Make Your Move event. Flex Cash provides buyers with added flexibility to put their savings toward eligible options based on their homebuying needs.
“The Make Your Move Sales Event is about giving buyers more opportunities to make homeownership a reality,” said Eric Lipar, Chief Executive Officer and Chairman of LGI Homes. “From valuable savings and financing incentives to move-in ready homes with upgrades already included, we are proud to offer buyers even more reasons to make their move into a new home.”
LGI Homes is known for its simplified homebuying process and commitment to providing exceptional value. Across communities nationwide, buyers can explore thoughtfully designed homes featuring desirable upgrades, functional floor plans and convenient locations.
The Make Your Move National Sales Event is available for a limited time at LGI Homes and Terrata Homes communities nationwide. Homebuyers are encouraged to visit a participating community to tour available move-in ready homes and learn more about incentives available in their market.
About LGI Homes
Headquartered in The Woodlands, Texas, LGI Homes, Inc. is a pioneer in the homebuilding industry, successfully applying an innovative and systematic approach to the design, construction and sale of homes across 36 markets in 21 states. LGI Homes has closed over 80,000 homes since its founding in 2003 and has delivered profitable financial results every year. Nationally recognized for its quality construction and exceptional customer service, LGI Homes was named to Newsweek’s list of the World’s Most Trustworthy Companies. LGI Homes’ commitment to excellence extends to its more than 1,000 employees, earning the Company numerous workplace awards at the local, state, and national level, including the Top Workplaces USA 2025 Award. For more information about LGI Homes and its unique operating model focused on making the dream of homeownership a reality for families across the nation, please visit the Company’s website at www.lgihomes.com.
MEDIA CONTACT: Rachel Eaton (281) 362-8998 ext. 2560
DENVER, Sept. 21, 2026 (GLOBE NEWSWIRE) — ArrowMark Financial Corp., (NASDAQ: BANX) (“ArrowMark Financial”), today announced that BANX’s estimated and unaudited Net Asset Value (“NAV”) as of August 31, 2026, was $21.00.
This estimated NAV is not a comprehensive statement of our financial condition or results for the month end.
About ArrowMark Financial Corp. ArrowMark Financial Corp. is an SEC registered non-diversified, closed-end fund listed on the NASDAQ Global Select Market under the symbol “BANX.” Its investment objective is to provide shareholders with current income. BANX pursues its objective by investing primarily in regulatory capital securities of financial institutions. BANX is managed by ArrowMark Asset Management, LLC. To learn more, visit ir.arrowmarkfinancialcorp.com, or contact Destra at 877.855.3434 or by email at BANX@destracapital.com.
Disclaimer and Risk Factors: There is no assurance that ArrowMark Financial will achieve its investment objective. ArrowMark Financial is subject to numerous risks, including investment and market risks, management risk, income and interest rate risks, banking industry risks, preferred stock risk, convertible securities risk, debt securities risk, liquidity risk, valuation risk, leverage risk, non-diversification risk, credit and counterparty risks, market at a discount from net asset value risk and market disruption risk. Shares of closed-end investment companies may trade above (a premium) or below (a discount) their net asset value. Shares of ArrowMark Financial may not be appropriate for all investors. Investors should review and consider carefully ArrowMark Financial’s investment objective, risks, charges and expenses. Past performance does not guarantee future results.
The Annual Report, Semi-Annual Report and other regulatory filings of the Company with the SEC are accessible on the SEC’s website at www.sec.gov and on the BANX’s website at ir.arrowmarkfinancialcorp.com.
FREDERICK, Md., Sept. 21, 2026 (GLOBE NEWSWIRE) — TOMI Environmental Solutions, Inc.® (“TOMI”) (NASDAQ: TOMZ), a global leader in disinfection and decontamination solutions, and Carbonium Core, Inc. (“Carbonium”), today announced that they have mutually agreed to terminate their previously announced definitive Merger Agreement, orginally dated June 28, 2026.
The decision to terminate the agreement was approved by TOMI’s Board of Directors on September 20, 2026. Both parties concluded that proceeding with the business combination is no longer in the best strategic or financial interest of their respective stakeholders.
Pursuant to the Merger Agreement, each party is responsible for its own fees and expenses incurred in connection with the Merger Agreement and the transactions contemplated thereby.
Dr. Halden Shane, CEO of TOMI Environmental Solutions commented, “TOMI has never been in a stronger position. Driven by the global adoption of our SteraMist solution, our business is delivering exceptional high-margin, recurring revenue growth and a healthy pipeline. Walking away cleanly from this transaction is in the best interest of our shareholders as we can now put refreshed focus on driving continued improvement in our operating results while protecting our clean capital structure. With our healthy backlog, the back half of the year should contribute to a strong 2026 for shareholders. In addition, we continue to pursue strategic partnerships with major players in our industry to expand market reach and sales opportunities.”
About TOMI™ Environmental Solutions, Inc.: Innovating for a safer world®
TOMI™ Environmental Solutions, Inc. (NASDAQ: TOMZ) is a global decontamination and infection prevention company providing environmental disinfection and bio-decontamination solutions through manufacturing, sales, and licensing of its Binary Ionization Technology® (BIT®) platform. Developed under a defense grant with DARPA, BIT® utilizes low-percentage hydrogen peroxide to produce ionized hydrogen peroxide (iHP®) fog. SteraMist® products serve hospitals, laboratories, government and military installations, cruise ships, office buildings, schools, restaurants, food processing facilities, and residences, delivering protection against a broad range of bacteria, viruses, mold, mycotoxins, and biological and chemical warfare agents. For additional information, please visit https://www.steramist.com or contact us at info@tomimist.com.
Forward-Looking Statements
This press release contains forward-looking statements that are based on current expectations, estimates, forecasts and projections of future performance based on management’s judgment, beliefs, current trends, and anticipated product performance. These forward looking statements include expectations regarding operating results and backlogs. Forward-looking statements involve risks and uncertainties that may cause actual results to differ materially from those contained in the forward-looking statements. These factors include, but are not limited to, our ability to acquire new customers and expands sales; our ability to maintain and manage growth and generate sales, our reliance on a single or a few products for a majority of revenues; the general business and economic conditions; and other risks as described in our SEC filings, including our Annual Report on Form 10-K for the fiscal year ended December 31, 2025 filed by us with the SEC and other periodic reports we filed with the SEC. The information provided in this document is based upon the facts and circumstances known at this time. Other unknown or unpredictable factors or underlying assumptions subsequently proving to be incorrect could cause actual results to differ materially from those in the forward-looking statements. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, level of activity, performance, or achievements. You should not place undue reliance on these forward-looking statements. All information provided in this press release is as of today’s date, unless otherwise stated, and we undertake no duty to update such information, except as required under applicable law.
LIMASSOL, Cyprus, Sept. 21, 2026 (GLOBE NEWSWIRE) — Toro Corp. (NASDAQ: TORO) (“Toro,” or the “Company”), a global energy transportation services provider, announces that, in relation to the previously announced spin-off of its wholly owned subsidiary, AI OKTO CORP. (“AI OKTO”), the record date has been set to October 1, 2026 (the “Record Date”), and the Company expects to complete the distribution of AI OKTO common shares on or about October 8, 2026. In the spin-off, Toro shareholders will receive one common share of AI OKTO for every eight Toro common shares held at the close of business on the Record Date.
Additional information regarding AI OKTO and the proposed spin-off transaction may be found in AI OKTO’s registration statement on Form 20-F filed with the Securities and Exchange Commission pursuant to the Securities Exchange Act of 1934. The proposed distribution and spin-off remain subject to, among other things, the registration statement on Form 20-F being declared effective and the approval of the listing of AI OKTO’s common shares on the Nasdaq Capital Market (“Nasdaq”). There can be no assurance that the distribution or the spin-off will occur or, if they do occur, of their terms or timing. A copy of the registration statement on Form 20-F is available at www.sec.gov. The information in the filed registration statement on Form 20-F is not final and remains subject to change.
As a result of “due bill” trading procedures expected to be established by Nasdaq, Toro common shares are expected to trade with due bills from the Record Date through and including the date of the distribution of the AI OKTO common shares. Accordingly, holders of Toro common shares as of the Record Date will need to hold such shares through and including the distribution date in order to receive the AI OKTO common shares distributed in the proposed spin-off.
This would mean that holders who purchase Toro common shares during the due bill period (even if the trades are to be settled after the due bill period) will be entitled to receive the spin-off distribution with respect to those shares. Conversely, sellers who sell Toro common shares during the due bill period (even if the trades are to be settled after the due bill period) will not be entitled to the spin-off distribution with respect to those shares.
Due bills obligate a seller of securities to deliver the distribution payable on such securities to the buyer. The due-bill obligations are customarily settled between the brokers representing buyers and sellers of the securities. The Company has no obligation for either the amount of the due bill or the processing of the due bill. Buyers and sellers of Toro’s common shares should consult their brokers before trading to ensure they understand the effect of Nasdaq’s due-bill procedures.
About Toro Corp.
Toro Corp. is a global energy transportation services provider, operating a modern fleet of oceangoing vessels. The Company’s fleet comprises four MR tanker vessels and two LPG carriers transporting refined petroleum products and petrochemical gases worldwide.
Toro is incorporated under the laws of the Republic of the Marshall Islands. The Company’s common shares trade on the Nasdaq Capital Market under the symbol “TORO.”
For more information, please visit the Company’s website at www.torocorp.com. Information on our website does not constitute a part of this press release.
Matters discussed in this press release may constitute forward-looking statements. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act of 1933, as amended and Section 21E of the Exchange Act. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements, which are other than statements of historical facts, and include statements relating to the expectation and timing of the completion of the spin-off transaction, the transaction terms, and Nasdaq trading procedures. We are including this cautionary statement in connection with this safe harbor legislation. The words “believe”, “anticipate,” “intend,” “estimate,” “forecast,” “project,” “plan,” “potential,” “will,” “may,” “should,” “expect,” “pending” and similar expressions identify forward-looking statements.
The forward-looking statements in this press release are based upon various assumptions, many of which are based, in turn, upon further assumptions, including, without limitation, our management’s examination of historical operating trends, data contained in our records and other data available from third parties. Although we believe that these assumptions were reasonable when made, because these assumptions are inherently subject to significant uncertainties and contingencies which are difficult or impossible to predict and are beyond our control, we cannot assure you that we will achieve or accomplish these forward-looking statements, including these expectations, beliefs or projections. We undertake no obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise. In addition to these important factors, other important factors that, in our view, could cause actual results to differ materially from those discussed in the forward‐looking statements include the effects of the proposed spin-off, our business strategy, expected capital spending and other plans and objectives for future operations, as well as those factors discussed under “Risk Factors” in our Annual Report on Form 20-F for the year ended December 31, 2025 and/or our other filings with the Commission which can be obtained free of charge on the Commission’s website at http://www.sec.gov. Except to the extent required by applicable law, we disclaim any intention or obligation to update publicly or revise any forward‐looking statements, whether as a result of new information, future events or otherwise.
INFORMATION STATEMENT WILL BE ACCESSIBLE THROUGH SEDAR+
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES
OTTAWA, Ontario, Sept. 21, 2026 (GLOBE NEWSWIRE) — (TSX: MNT/MNT.U) The Royal Canadian Mint (the “Mint”) announced today that it has launched a follow-on offering of exchange-traded receipts (“ETRs”) under the Mint’s Canadian Gold Reserves program (the “Offering”). The Mint’s outstanding ETRs are listed on the Toronto Stock Exchange in Canadian and U.S. dollars under the symbols “MNT” and “MNT.U”, respectively.
Each ETR provides its holder with direct legal and beneficial ownership in physical gold bullion held in the custody of the Mint at its facilities in Ottawa, Ontario. The ETRs to be issued under the Offering will be identical to and fully fungible with the ETRs currently outstanding. The net proceeds of the Offering will be used to purchase gold bullion on behalf of the purchasers of the ETRs.
Subject to certain restrictions, ETR holders are entitled to redeem their ETRs for physical gold bullion with a minimum purity of 99.99% or for cash.
The size of the Offering and the price per ETR will be determined at the time of pricing. The closing of the Offering is expected to occur on or about September 24, 2026 and will be subject to market and other customary conditions, including approval of the Toronto Stock Exchange.
The Offering is being made by a syndicate of underwriters co-led by TD Securities Inc. and National Bank Financial Inc. The Offering is being made on a prospectus-exempt basis pursuant to the terms of exemptive relief orders issued in favour of the Mint by the Ontario Securities Commission.
Important information about the ETRs and the Offering is contained in the information statement dated September 21, 2026 (the “Information Statement”). The Information Statement will be accessible on SEDAR+ at www.sedarplus.ca and on the Mint’s website at www.reserves.mint.ca. Purchasers will be notified of the availability of the Information Statement through their investment dealer. In addition, a copy of the Information Statement may be obtained, without charge, from TD Securities Inc. (sdcconfirms@td.com by email or (289) 360-2009 by telephone) or National Bank Financial Inc. (NBF-Syndication@bnc.ca by email or (416) 869-8414 by telephone).
ETR holders have no recourse to the Mint or the Government of Canada for any loss on their investment.
The ETRs have not been and will not be registered under the United States Securities Act of 1933, as amended, or any state securities laws, and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements. This news release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any offer, solicitation or sale of the ETRs in any jurisdiction in which such an offer, solicitation or sale would be unlawful.
Additional information on the Canadian Gold Reserves program and the ETRs is available on the Canadian Gold Reserves’ website at www.reserves.mint.ca and on the Mint’s issuer profile on SEDAR+ at www.sedarplus.ca.
About the Royal Canadian Mint
The Royal Canadian Mint is the Crown corporation responsible for the minting and distribution of Canada’s circulation coins. The Mint is one of the largest and most versatile mints in the world, producing award-winning collector coins, market-leading bullion products, as well as Canada’s prestigious military and civilian honours. As an established London Good Delivery and COMEX-approved refiner, the Mint also offers a full spectrum of best-in-class gold and silver refining services. The Mint has issued exchange-traded receipts under its Canadian Gold Reserves (TSX: MNT/MNT.U) and Canadian Silver Reserves (TSX: MNS/MNS.U) programs, which provide holders with direct legal and beneficial ownership in physical bullion held in the custody of the Mint at its facilities. For more information on the Mint, its products and services, visit www.mint.ca.
Certain information in this news release contains forward-looking information within the meaning of applicable securities laws in Canada. The forward-looking information in this news release includes, without limitation, statements regarding the terms of the Offering. All forward-looking information is given pursuant to the safe harbour provisions of applicable Canadian securities legislation. The words “anticipates”, “believes”, “budgets”, “could”, “estimates”, “expects”, “forecasts”, “intends”, “may”, “might”, “plans”, “projects”, “schedule”, “should”, “will”, “would” and similar expressions identify forward-looking information, although not all forward-looking information contains these identifying words. The forward-looking information reflects management’s current beliefs with respect to anticipated events, are based on assumptions developed using information currently available to the Mint’s management and are subject to inherent risks and uncertainties surrounding future expectations generally. Although the Mint believes that the forward-looking information is based on information and assumptions which are current, reasonable and complete, these statements are necessarily subject to a variety of risks and uncertainties. Forward-looking information should not be read as guarantees of future events, performance or results, and will not necessarily be accurate indications of whether, or the times at which, such events, performance or results will be achieved. All the information in this news release containing forward-looking information is qualified by these cautionary statements.
For additional information on risk factors that have the potential to affect the ETRs, the Canadian Gold Reserves program or the Mint, reference should be made to the Information Statement, which may be accessed in the manner described above. Readers are urged to consider the risks, uncertainties, and assumptions carefully in evaluating the forward-looking information and are cautioned not to place undue reliance on such information and statements.
Except as required by law, the Mint undertakes no obligation to revise or update any forward-looking information as a result of new information, future events or otherwise after the date hereof.
For more information, please contact:
Media Inquiries Alex Reeves Senior Manager, Public Affairs Royal Canadian Mint 613-884-6370 reeves@mint.ca
Investor Relations Frank Caterina Program Associate, ETR Investor Relations Royal Canadian Mint 1-866-677-1477 reserves@mint.ca
This achievement places the Waterless Beauty pioneer among a very small group of beauty companies with their own biodynamic agricultural resources at the source of their beauty
Thomas_Lommel_Olive_Tree
Olive Tree Farmer Thomas Lommel working with the Company’s olive trees in Andalusia, Spain.
SANTA MONICA, CA, Sept. 21, 2026 (GLOBE NEWSWIRE) — Oliveda International, Inc. (OTCID: OLVI) today announced that olive groves owned by its Olive Tree People Inc. subsidiary have successfully completed their Demeter certification audit, placing the Waterless Beauty pioneer among a very small group of beauty companies worldwide with their own biodynamic agriculture resources at the source of their beauty.
Most beauty companies buy ingredients. OLIVE TREE PEOPLE grows them.
Very few beauty companies in the world can say what OLIVE TREE PEOPLE can say today: Our beauty begins on our own land, with our own trees — and our first olive groves have now successfully completed their Demeter audit with outstanding results. Formal certification is pending completion of the certification process.
This places OLIVE TREE PEOPLE among a remarkably small group in the global beauty industry: companies whose relationship with nature doesn’t begin with purchasing a botanical ingredient from a supplier, but with their own agricultural resources at the very source.
For more than 20 years, OLIVE TREE PEOPLE has cultivated and protected mountain olive trees in Andalusia, Spain — not simply as inspiration for its products, but as the agricultural origin of its beauty philosophy and many of its most important ingredients.
The company doesn’t simply know where its ingredients come from.
It knows the land. It knows the trees. It grows them.
For OLIVE TREE PEOPLE, agriculture has never been a supplier story.
IT IS WHERE BEAUTY BEGINS.
The soil. The trees. The leaves. The olives. The harvest. The extraction. The formulation. The skin. One living cycle.
FROM A DEMETER FARM AT 16 TO HIS OWN OLIVE GROVES
For founder Thomas Lommel, the moment closes a circle that began decades before OLIVE TREE PEOPLE existed. At 16 years old, while attending a Waldorf school in Germany, Lommel completed his first agricultural internship on a Demeter farm.
What began there as an encounter with a radically different understanding of agriculture — one in which soil, plants, animals and people are understood as parts of one living agricultural organism — would eventually become part of the philosophy behind his life’s work.
Years later, that journey led him to the mountain olive trees of Andalusia and, ultimately, to OLIVE TREE PEOPLE.
“We do not take from nature and then attempt to give something back,” said Lommel. “We create a living cycle.”
That distinction is fundamental.
The olive groves are not a sustainability project attached to a beauty company.
They are part of the beauty company.
OLIVE TREE PEOPLE grows and protects its own olive trees, works with their leaves and olives, extracts bioactive substances at the heart of its formulations, and develops Waterless Beauty around the olive tree rather than around water as the primary ingredient.
BEAUTY HAS TALKED ABOUT FARM-TO-FACE.
OLIVE TREE PEOPLE ACTUALLY OWNS THE FARM.
Traceability has become a major word in beauty.
Brands talk about knowing where an ingredient was grown.
OLIVE TREE PEOPLE goes considerably further.
The company is vertically connected all the way back to the living tree.
From its own agricultural resources in Andalusia to extraction, formulation and finally the skin, the company is building a beauty model in which agriculture isn’t hidden somewhere at the beginning of a supply chain.
Agriculture is part of the brand itself, and now, with its first olive groves successfully completing their Demeter audit, that agricultural foundation is moving toward one of the world’s most demanding biodynamic standards.
For Lommel, this isn’t a new sustainability strategy. It is the continuation of an idea that began when he was 16.
Beauty shouldn’t take something from nature and later ask how to compensate for it.
BEAUTY CAN BE A CIRCLE FROM THE BEGINNING.
So perhaps last Friday wasn’t really about passing an audit.
It was about something much bigger: One of the very few beauty companies in the world with its own agricultural resources taking those resources to an extraordinary biodynamic standard.
Rooted. Living. Circular.
And beginning with its own trees.
About Olive Tree People Olive Tree People is a pioneer and leading force in waterless beauty. Instead of using the conventional water phase found in most skincare products, the company replaces water with its proprietary olive leaf cell elixir and combines it with powerful olive-tree ingredients, including Hydroxytyrosol.
Founded by olive tree farmer Thomas Lommel, Olive Tree People develops skincare, beauty and holistic experiences based on more than 20 years of work with mountain olive trees and the principles of Olive Tree Therapy.
About Oliveda International, Inc. Oliveda International, Inc. and its subsidiary, Olive Tree People Inc., as well as the European companies, Olive Tree People Europe AG, Oliveda Deutschland GmbH, and Olive Tree Farmers SL, were founded by the German real estate investor Thomas Lommel. The companies possess over 20 years of experience in management and organic certification growing mountain olive trees; in the extraction of first-class, internationally award-winning extra virgin olive oils; the extraction of hydroxytyrosol; and the production and distribution of cosmetic and holistic waterless products related to the olive tree. Lommel is the inventor of the “Olive Tree Therapy 10 Years in 14 Days” as well as the inventor of olive matcha, which is based on the ground olive leaf. Also unique is the coffee replacement developed by Lommel, which is based on the olive leaf and hydroxytyrosol. In addition, Lommel is successfully active in the rapidly growing mindfulness industry with the olive tree sound bath meditation he developed and the frequencies of his olive trees, which he makes available worldwide.
In addition to the registered beauty brands, Oliveda and LA Dope, as well as the brands Olive Rose, OLIVE re:connected to Nature, The Intuition of Nature, Olive Mush, Baby & Mom, and Is That Matty?, Lommel is the region’s largest conservationist and protector of over 30,000 one-hundred-year-old mountain olive trees. With his Thomas Lommel Foundation, he brings the water that he does not use into his waterless beauty products to the people of Africa by building water wells on site.
The company’s direct-to-consumer network includes tens of thousands of Waterless Beauty Consultants in North America and Europe. In addition to online sales and a Europe-wide branch network of thousands of retail stores, Oliveda Deutschland GmbH operates its own flagship stores in Berlin and Düsseldorf.
The brand’s treatment concepts are unique worldwide, and their effectiveness has been confirmed by conventional medicine. Read our book The Olive Tree Therapy 10 Years in 14 Days. Waterless beauty has been called “The Next Big Thing” in articles in U.S. Vogue, Harper’s Bazaar, InStyle, Elle, Madame, Forbes, and many other industry publications, as well as by Mintel, a world-leading futurology institute. Gigi Hadid and many other celebrities are already Oliveda fans and support its success. Further information on Oliveda International, Inc. and its subsidiaries and associate companies and brands can be found at www.olivetreepeople.com
Forward-Looking Statements This press release may contain statements, estimates or projections that constitute “forward-looking statements” pursuant to the safe harbor provisions of the U.S. federal securities laws. Generally, the words “believe,” “expect,” “intend,” “estimate,” “anticipate,” “project,” “will” and similar expressions identify forward-looking statements, which generally are not historical in nature. Forward-looking statements are subject to certain risks and uncertainties, which may be found in the Company’s filings with OTC Markets Group Inc., that could cause actual results to differ materially from the Company’s historical experience and present expectations or projections. Investors should not place undue reliance on forward-looking statements, which speak only as of the date they are made. The Company expressly disclaims any obligation or intention to publicly update or revise any forward-looking statements unless otherwise required by law.
West Palm Beach, Sept. 21, 2026 (GLOBE NEWSWIRE) — Terminal1, the operating system built for public companies, announced today that BioStem Technologies, Inc. (NASDAQ: BSEM) has joined the Terminal1 platform.
BioStem Technologies will utilize Terminal1’s integrated suite of shareholder intelligence, investor communications, and digital investor relations tools, giving the company a centralized platform to better understand its shareholder base, communicate with investors, and measure engagement across its investor ecosystem.
The addition of BioStem Technologies represents another step in Terminal1’s continued expansion as public companies increasingly look to consolidate traditionally fragmented investor relations functions into a single system.
“Public companies have historically relied on multiple vendors, disconnected data, and separate platforms to manage their investor ecosystem,” said Wesley De Souza, CDO, Terminal1. “Terminal1 was built to bring those functions together. We’re excited to welcome BioStem Technologies to the platform and continue demonstrating how shareholder data can be transformed into actionable intelligence.”
Through Terminal1, companies can access a growing suite of capabilities including:
Shareholder Intelligence — Normalize and analyze shareholder and NOBO data to identify ownership trends, active buyers and sellers, shareholder concentration, geographic distribution, and changes over time.
Investor Communications — Manage email and SMS communications from a centralized platform while tracking delivery, engagement, and subscriber activity.
IR Website & Analytics — Manage a company’s investor-facing digital presence while measuring investor behavior, traffic sources, engagement, and conversions.
Integrated Investor Data — Connect shareholder ownership, communications, and digital engagement to provide management teams with a more complete view of their investor ecosystem.
The platform is designed to provide CEOs, CFOs, investor relations teams, and other public-company executives with greater visibility into not only who owns their stock, but also how investors are interacting with the company.
“Adding BioStem Technologies is another important milestone for Terminal1,” added De Souza. “Our goal is straightforward: give public companies one system to understand their shareholders, communicate with the market, and measure what is actually driving investor engagement.”
Terminal1 continues to expand its public-company customer base as it builds out additional capabilities across shareholder intelligence, communications, analytics, and investor relations infrastructure.
About Terminal1
Terminal1 is an operating system built for public companies. The platform brings together shareholder intelligence, investor communications, IR website infrastructure, and investor analytics within one centralized system.Terminal1 helps public companies better understand their shareholders, engage their investor audience, and turn investor data into actionable insights.
(Nasdaq: BSEM): BioStem Technologies, Inc. is a publicly traded, biomedical innovator, focused on developing, manufacturing and commercializing advanced allograft solutions derived from perinatal tissue. The company leverages its industry-leading proprietary BioRetain®, CryoTek® and SteriTek® processing technologies, designed to optimize the preservation of the natural properties of these tissues, supporting their use in clinical settings. Its allografts are used by clinicians across a wide range of specialties. With a growing portfolio of products, expanding clinical research initiatives, and a national commercial footprint, BioStem is committed to advancing innovation in regenerative medicine.
BioStem Technologies’ quality management system and standard operating procedures have been reviewed and accredited by the Association for Advancing Tissue and Biologics (“AATB”). These systems and procedures are established in compliance with current Good Tissue Practices (“cGTP”) and current Good Manufacturing Practices (“cGMP”). BioStem’s portfolio of quality brands includes its Neox®, Clarix®, VENDAJE® and American Amnion™ product lines.
PONTE VEDRA, Fla., Sept. 21, 2026 (GLOBE NEWSWIRE) — Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a late-stage biopharmaceutical company advancing specialized therapies for critical care cardiology and orphan cardiovascular conditions, announced that CEO Quang X. Pham will participate in a webcast presentation and host one-on-one meetings with investors at the Lytham Partners Fall 2026 Investor Conference, taking place virtually on September 29-30, 2026.
Company Webcast
The webcast presentation will take place at 10:15 a.m. ET on Tuesday, September 29, 2026. The webcast can be accessed by visiting the conference website at https://lythampartners.com/fall2026/ or directly at https://app.webinar.net/45v0RKgRmKD. The webcast will also be available for replay following the event.
Cadrenal Therapeutics, Inc. is a late-stage biopharmaceutical company advancing specialized therapies for critical care cardiology and orphan cardiovascular conditions. The Company’s pipeline includes CAD-1005, tecarfarin, and frunexian. CAD-1005 is a novel investigational therapeutic in development for the treatment of heparin-induced thrombocytopenia (HIT) and Cardiac Surgery-Associated Acute Kidney Injury (CSA-AKI). CAD-1005 is designed to selectively inhibit 12-lipoxygenase (12-LOX), an enzyme central to platelet immune activation and thrombo-inflammatory signaling in HIT. CAD-1005 is intended to be used alongside existing standards of care and is being developed to address the underlying biological mechanisms that drive disease progression. CAD-1005 has an Orphan Drug Designation (“ODD”) from the U.S. Food and Drug Administration (“FDA”) for prophylaxis of thrombosis in patients with HIT, FDA Fast Track designation for the treatment and prevention of HIT, and an orphan designation from the European Medicines Agency for the treatment of platelet-activating factor 4 disorders. Second-generation 12-LOX oral therapeutics (CAD-2000) are also in development for chronic indications.
The Company’s broader pipeline includes tecarfarin, a late-stage oral vitamin K antagonist designed to prevent heart attacks, strokes, and deaths from blood clots in patients requiring chronic anticoagulation, including those with end-stage kidney disease and atrial fibrillation, those with left ventricular assist devices, and potentially those with Kawasaki disease (KD), an acute, self-limited, febrile illness that primarily affects children under 5 years old and is the leading cause of acquired heart disease in developed countries. The Company recently submitted a request to the FDA for Rare Pediatric Disease Designation (RPDD) for tecarfarin for “Prevention of the Formation of Life-Threatening Blood Clots Inside Coronary Artery Aneurysms in Children with Kawasaki Disease”. Tecarfarin has also received Orphan Drug and Fast Track designations from the FDA.
Transaction provides $247 million in gross proceeds to support newcleo’s U.S. and European growth, advance its lead-cooled fast reactor and MOX nuclear fuel production towards commercialization
newcleo’s ordinary shares to begin trading on Nasdaq under the ticker symbol “NWCL” on September 22, 2026
Highly experienced Board of Directors to be led by industry veteran Jeffrey Lyash, former President and CEO of the Tennessee Valley Authority and Ontario Power Generation
PARIS and NEW YORK, Sept. 21, 2026 (GLOBE NEWSWIRE) — newcleo plc (“newcleo” or the “Company”), a pioneer in advanced modular reactor (“AMR”) technology and nuclear fuel manufacturing, today announced that the Company has closed its previously announced business combination (the “Business Combination”) with NewHold Investment Corp III (Nasdaq: NHIC) (“NewHold”), a publicly listed special purpose acquisition company.
The close of the Business Combination follows approval by NewHold’s shareholders at an Extraordinary General Meeting held on September 17, 2026. newcleo’s ordinary shares and warrants will begin trading on the Nasdaq Global Select Market under the ticker symbols “NWCL” and “NWCLW”, respectively, on September 22, 2026.
The transaction establishes a strong capital foundation for newcleo as a public company, directly providing approximately $247 million of gross proceeds to advance newcleo’s U.S. and European growth and move its lead-cooled fast reactor and MOX nuclear fuel production towards commercialization.
The transaction valued newcleo at a pre-money equity value of approximately $2.4 billion. Gross proceeds received by the Company were comprised of an oversubscribed $216 million PIPE and $31 million provided from NewHold’s trust account at time of closing.
Up to an additional $75 million may become available to the Company under the previously disclosed forward purchase agreement, as described in the Current Report on Form 8-K filed by NewHold on September 11, 2026.
Additionally, newcleo has also raised close to $20 million since the Business Combination announcement, bringing total funds raised to over $1 billion to-date, inclusive of this transaction.
newcleo intends to deploy the additional capital to support its global growth, completing and operating its 10MWth non-nuclear demonstrator in Italy, advancing regulatory and licensing interactions with U.S. and French nuclear safety regulators, and to continue pursuing commercial opportunities to deploy its reactors and fuel manufacturing facilities in the U.S. and Europe.
“Today we are reaching a new steppingstone that sets newcleo up for long-term success. We look forward to continuing to deliver on our ambitious projects to bring about safe, clean, sustainable and competitive nuclear energy, and to do so from within the world’s greatest market for innovation capital,” said Stefano Buono, CEO and Co-Founder of newcleo. “We would like to thank our legacy shareholders, who have been with us in developing newcleo as a company at the forefront of nuclear innovation, as well as the great team at NewHold, their shareholders, the PIPE investors who have joined the transaction and those who will support our long-term ambition as we become a Nasdaq-listed company. We couldn’t have achieved this impressive level of development without them and we look forward to continuing on this path with the people that are building our success from within the company every day.”
“newcleo’s public listing is the culmination of the hard work our two teams have put into this transaction, and we’re glad to see it through to such an incredibly successful completion,” said Kevin Charlton, CEO of NewHold. “We believe newcleo’s technology, spanning both reactor and fuel businesses, is well positioned to win in the growing global nuclear industry and serve the growing need for reliable, low-carbon power.”
newcleo’s existing management team will continue to lead the combined company. Existing newcleo shareholders rolled over 100% of their equity, demonstrating strong confidence in the Company’s prospects. The transaction was unanimously approved by the boards of directors of both NewHold and newcleo.
Following the closing of the transaction, newcleo’s Board of Directors is composed of an experienced group of leaders with expertise spanning nuclear technology, capital markets, and public company governance. The board is chaired by Jeffrey Lyash, former President and CEO of the Tennessee Valley Authority and Ontario Power Generation Inc., who brings more than 40 years of experience in the power generation, transmission, and distribution sectors. The board also includes Stefano Buono, Founder and CEO of newcleo and Andrea Ruben Levi, who previously served as Chairman and continues on the board as Chair of the Compensation Committee. Completing the public company board are Anne-Francois de Bourdoncle de Saint Salvy, Manfredi Lefebvre D’Ovidio, Heinz Maeusli, Raffaele Petrone, Elisabeth Rizzotti and Suzy Taherian.
Advisors
Guggenheim Securities acted as financial advisor and capital markets advisor to newcleo. Goldman Sachs & Co. LLC acted as lead placement agent to newcleo. BTIG acted as placement agent and capital markets advisor to newcleo. Davis Polk & Wardwell LLP (New York) and CMS Cameron McKenna Nabarro Olswang LLP (London) acted as legal advisor to newcleo. Loeb & Loeb LLP acted as legal counsel to NewHold. Latham & Watkins LLP acted as legal counsel to the placement agents. ICR acted as strategic communications advisor to newcleo.
About newcleo
newcleo is an innovative nuclear technology company developing advanced modular reactors and nuclear fuel designed to deliver clean, safe and sustainable energy at competitive costs. newcleo’s technology combines lead-cooled fast reactors with fuel manufactured from recycled nuclear materials, with the aim of providing abundant and reliable electricity and heat to industrial users while enabling the closure of the nuclear fuel cycle. newcleo brings together more than 900 highly skilled employees across Europe and the United States, spanning reactor and fuel design, engineering, and manufacturing. Through a vertically integrated supply chain and a growing network of strategic partnerships, newcleo is working to turn proven scientific and engineering solutions into deployable nuclear energy assets. For more information visit www.newcleo.com.
Forward-Looking Statements
This press release contains certain forward-looking statements within the meaning of the U.S. federal securities laws. All statements contained in this press release other than statements of historical fact, including, without limitation, statements regarding the completed Business Combination between NewHold and newcleo; the anticipated benefits of the transaction; expected trading of the combined company’s securities on Nasdaq; the completion of investments from certain institutional investors; the expected amount of gross proceeds from any investments or other financing arrangements; the anticipated use of proceeds from such investments or financing arrangements; newcleo’s development and commercialization of its lead-cooled fast reactor technology, mixed-oxide fuel capabilities and related products and services; the expected timing, cost, performance and benefits of newcleo’s demonstration projects, fuel facilities, reactor deployments and licensing activities; newcleo’s ability to execute its business strategy, develop its technology, obtain required regulatory approvals, permits and licenses, enter into commercial arrangements, achieve its market opportunity and positioning and support the growth of advanced nuclear energy; newcleo’s expectations regarding strategic partnerships, customer demand, project pipeline, revenue streams, capital expenditures and financing needs; and other statements regarding management’s intentions, beliefs, or expectations with respect to newcleo’s future performance, are forward-looking statements. Forward-looking statements are often identified by the use of words such as “anticipate,” “believe,” “continue,” “could,” “develop,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “seek,” “should,” “target,” “will,” “would,” and similar expressions, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements are based on newcleo’s current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such forward-looking statements. You should carefully consider the foregoing factors and the other risks and uncertainties described in other documents filed from time to time by newcleo with the SEC. Additional risks and uncertainties not currently known or that are currently deemed immaterial may also cause actual results to differ materially from those expressed or implied by such forward-looking statements. Readers are cautioned not to put undue reliance on forward-looking statements, and newcleo does not assume any obligation or intend to update or revise these forward-looking statements, each of which is made only as of the date of this press release.
